Income statement
AUD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5M | 4M | 4M | 5M | 4M |
| Gross Profit | 5M | 4M | 4M | 5M | 4M |
| Operating Income | -15M | -20M | -15M | -16M | -15M |
| EBITDA | -15M | -20M | -15M | -15M | -15M |
| Net Income | -12M | -19M | -14M | -13M | -15M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.055
+0.00% today
1Y Change
-63.33%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 244 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Alterity Therapeutics Limited (PRNAF) is a Healthcare stock with a market cap of $110.00M and listed on OTC. The stock last traded around $0.06 and down 63.3% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +35.3%, EPS growth of +63.5%, a dividend yield of 0.0%. What stands out right now is revenue +35.3%, EPS +63.5%, free cash flow +9.2% with operating margin -525.6% and ROIC -31.3%. Valuation already assumes a fairly strong business story at price/sales 29.8. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PRNAF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRNAF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PRNAF Max Drawdown
-98.15%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PRNAF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$4.3M
-15.3% YoY
FY Net Income
-$15.3M
-19.2% YoY
Free Cash Flow
-$17.3M
-39.5% YoY
Revenue Growth
+35.3%
EPS Growth
+63.5%
Gross Margin
96.8%
Net Margin
-380.7%
Income statement
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 5M | 4M | 4M | 5M | 4M |
| Gross Profit | 5M | 4M | 4M | 5M | 4M |
| Operating Income | -15M | -20M | -15M | -16M | -15M |
| EBITDA | -15M | -20M | -15M | -15M | -15M |
| Net Income | -12M | -19M | -14M | -13M | -15M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
AUD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 33M | 13M | 16M | 35M | 28M |
| Total Assets | 46M | 19M | 27M | 41M | 34M |
| Total Liabilities | 4M | 5M | 5M | 6M | 3M |
| Shareholder Equity | 42M | 14M | 23M | 35M | 30M |
| Total Debt | 155K | 159K | 210K | 117K | 66K |
| Net Debt | -33M | -12M | -16M | -35M | -28M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
17M
-40.5% YoY
Capital Expenditures
3K
+96.6% YoY
Free Cash Flow
17M
-39.5% YoY
Key ratios
Gross Margin
96.8%
Operating Margin
-525.6%
Net Margin
-380.7%
ROE
-30.2%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.